Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913189 | 0.93 | LPL (0.35) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL12357206 | 0.90 | LPL (0.36) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL2393633 | 0.87 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12760441 | 0.87 | LPL (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12357207 | 0.85 | LPL (0.39) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL13218909 | 0.80 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL9913718 | 0.79 | ALOX5AP (0.30) | ALOX5APFEN1 | |
| SCHEMBL12226114 | 0.78 | GPR3 (0.40) | ALOX5APFEN1GRM2 | |
| SCHEMBL587211 | 0.78 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14235285 | 0.77 | ALOX5AP (0.39) | ALOX5APFEN1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | LPL 105/4885LIPG 711/4885ALOX5AP 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.